Skip to main navigation
Skip to search
Skip to main content
Athabasca University Home
Search content at Athabasca University
Home
Researchers
Research Outputs
Research Activities
Datasets
News Media
Research units
Assets and Initiatives
Research Projects
Research Prizes
Impacts
Inhaled magnesium sulfate in the treatment of acute asthma
Rachel Knightly
, Stephen J. Milan
, Rodney Hughes
,
Jennifer A. Knopp-Sihota
, Brian H. Rowe
, Rebecca Normansell
, Colin Powell
Faculty of Health Disciplines
St George's Hospital
Lancaster University
Sheffield Teaching Hospitals NHS Foundation Trust
University of Alberta
Cardiff University
Research output
:
Contribution to journal
›
Review article
›
peer-review
24
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inhaled magnesium sulfate in the treatment of acute asthma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Asthma
100%
Nebulized Magnesium Sulfate
100%
Magnesium Sulfate
100%
Confidence Interval
58%
Ipratropium
41%
Adverse Events
33%
Serious Adverse Events
33%
Intervention Group
25%
Risk Ratio
25%
Hospital Admission
25%
Risk Difference
25%
Peak Expiratory Flow Rate
25%
Between-group Difference
16%
Pediatric Patients
16%
Admission to Hospital
16%
Lung Function
16%
Methodological Quality
16%
Lung Function Parameters
16%
Data Extraction
8%
Cochrane
8%
Moderate to Severe
8%
Missing Data
8%
Clinically Significant
8%
Airway
8%
Risk of Bias
8%
Selection Criteria
8%
Review Update
8%
Trial Registries
8%
Between-group
8%
Review Authors
8%
Search Methods
8%
Standardized Mean Difference
8%
Life-threatening
8%
Adult Patients
8%
Patient-completed
8%
Treatment Options
8%
Placebo-controlled Trial
8%
Combination Treatment
8%
Forced Expiratory Volume in 1 Second (FEV1)
8%
Effect Estimates
8%
Online Trials
8%
Clinical Severity
8%
Asthma Exacerbation
8%
Core Outcome Set
8%
Readmission
8%
Group Risk
8%
Event Risk
8%
Trialists
8%
Pooling Effect
8%
Data Risk
8%
Severe Attack
8%
Acute Exacerbation
8%
Escalation of Care
8%
Design Outcomes
8%
Vital Signs
8%
Design Definition
8%
Design Intervention
8%
Uncertain Results
8%
Systemic Steroids
8%
Historical Comparison
8%
Specific Intent
8%
Point Estimate
8%
Data Pooling
8%
Medicine and Dentistry
Asthma
100%
Magnesium Sulfate
100%
Lung
66%
Ipratropium Bromide
66%
Attributable Risk
50%
Peak Expiratory Flow
50%
Pediatrics Patient
33%
Randomized Controlled Trial
33%
High Risk Population
16%
Vital Sign
16%
Asthma Exacerbation
16%
Lung Function
16%
Placebo
16%
Treatment Option
16%
Nursing and Health Professions
Confidence Interval
100%
Magnesium Sulfate
100%
Asthma
100%
Ipratropium Bromide
57%
Peak Expiratory Flow
42%
Attributable Risk
42%
Efficacy
42%
Pediatrics Patient
28%
Hospital Readmission
14%
Data Extraction
14%
High Risk Population
14%
Vital Sign
14%
Placebo
14%
Pharmacology, Toxicology and Pharmaceutical Science
Magnesium Sulfate
100%
Asthma
100%
Ipratropium Bromide
57%
Randomized Controlled Trial
28%
Placebo
14%
Biochemistry, Genetics and Molecular Biology
Agonist
100%
Magnesium Sulfate
100%
Ipratropium Bromide
33%
Peak Expiratory Flow
25%
Randomized Controlled Trial
16%
High Risk Population
8%
Lung Function
8%
Data Extraction
8%
Immunology and Microbiology
Asthma
100%
Agonist
100%
Ipratropium Bromide
33%
Peak Expiratory Flow
25%
Data Extraction
8%
Lung Function
8%
High Risk Population
8%
Asthma Exacerbation
8%
Airway
8%